Cardiogenic shock occurs when the heart cannot pump enough blood.1 Despite the use of extracorporeal life support (ECLS), mortality remains high.1 The DanGer Shock study showed that the Impella CP heart pump provides a long-term survival benefit that increases year after year.3 In the LEVOECMO randomized clinical trial, levosimendan facilitated weaning from ECMO in patients with severe cardiogenic shock.[The ECLS-SHOCK trial analysis confirmed that ECMO complications are not a cause of mortality in MI-induced shock.2 The FRENSHOCK trial examined the effect of timing, modality, and indications of acute renal replacement therapy on prognosis.2 The article was published in the New England Journal of Medicine, Volume 394, Issue 1, Pages 62-77, January 1, 2026.